Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28804053 | 0.94 | HSD11B1 (0.44) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL28804055 | 0.94 | HSD11B1 (0.44) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL228179 | 0.94 | HSD11B1 (0.46) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL1958715 | 0.92 | HSD11B1 (0.43) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL1204990 | 0.92 | HSD11B1 (0.43) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL23842059 | 0.92 | HSD11B1 (0.43) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL26667536 | 0.92 | HSD11B1 (0.43) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL1204992 | 0.92 | HSD11B1 (0.43) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL13698817 | 0.92 | HSD11B1 (0.43) | HSD11B1ASGR1KDM4DCHRM2CHRM1 | |
| SCHEMBL26667529 | 0.92 | HSD11B1 (0.43) | HSD11B1ASGR1KDM4DCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2025-05-15 | — | — | US | disclosed |
| CN-114466844-B | N- (1H-imidazol-2-yl) benzamide compound and pharmaceutical composition comprising same as active ingredient | 康佳诺医疗科技发展有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113563245-B | Substituted pyrrolidines and their use in medicine | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-117247321-A | Preparation method of anhydrous N-methylcyclopropylamine hydrochloride | 浙江沙星科技股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116997548-A | HTT modulators for the treatment of huntington's disease | CHDI基金会股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220348560-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2022-11-03 | — | — | US | disclosed |
| EP-0823413-B1 | Intermediates for the preparation of benzoheterocyclic compounds | OTSUKA PHARMA CO LTD (JP) | 2002-02-13 | — | — | EP | disclosed |
| US-5811576-A | 1-CARBOXY-2-LOWERALKYL-3,4,6-TRI(HALO)BENZENES; GRAMPOSITIVE AND-NEGATIVE BACTERIA; INFECTIONS; STERILIZATION OF MEDICAL EQUIPMENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5723648-A | Intermediates for anti-microbial benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0823413-A2 | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| US-5591744-A | 1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLATE DERIVATIVES; MICROBIOCIDES | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-01-07 | — | — | US | disclosed |
| US-5563138-A | 4-OXOQUINOLINE-3-CARBOXYLIC ACID COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0287951-B1 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5495020-A | CHEMICAL INTERMEDIATE FOR BACTERICIDES, MICROBIOCIDES, DISINFECTANTS; SIDE EFFECT REDUCTION, ABSORPTION | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-02-27 | — | — | US | disclosed |
| US-5290934-A | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0565132-A2 | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | HSD11B1 483/4885ASGR1 393/4885KDM4D 3174/4885 |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | HSD11B1 3470/4885ASGR1 3862/4885KDM4D 2930/4885 |
| US-20220348560-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | IRAK4, IRAK1, IRAK2 | HSD11B1 3086/4885ASGR1 2402/4885KDM4D 100/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | HSD11B1 2227/4885ASGR1 1370/4885KDM4D 234/4885 |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | HSD11B1 381/4885ASGR1 3535/4885KDM4D 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.